Amgen, Inc. was the first to bring a KRAS G12C inhibitor to market with the US Food and Drug Administration approval of Lumakras (sotorasib) a year ago and Mirati Therapeutics, Inc. is on track for a second-place finish with potential FDA approval of adagrasib in December of this year. However, both companies still have a lot of work to do to illustrate the best use of their therapies and each attempted to advance that understanding at the American Society of Clinical Oncology meeting.
As Amgen vice president of late-stage oncology development I-Fen Chang noted in an interview with Scrip, “We're just at the...